Richard Kent, former chief executive officer at Serenex in the Triangle, is joining venture capital firm .

As a venture partner, Kent will focus on life-science investments. He left Serenex this spring.

Pfizer acquired Serenex in April. Intersouth was an investor in Serenex.

Kent, who holds a medical degree, also was former CEO at Arden Pharmaceuticals. Before becoming an entrepreneur, Kent was senior vice president for global medical affairs and chief medical officer at GlaxoSmithKline.

“We are pleased to add Rick’s industry experience, knowledge and contacts to the Intersouth team,” said Dennis Dougherty, an Intersouth partner and the firm’s founder. “Having worked with Rick over the last several years as the CEO of one of our portfolio companies, we knew he’d fit in with the Intersouth team – we’re excited to have him join us. His understanding of both the startup world and the large pharmaceutical world that is a critical partner to so many of our companies will be invaluable both to our investment process and to helping our growing portfolio companies.”

Kent received his medical degree from the University of California, San Diego, and received medical training at Harvard, Stanford and Duke. He also was a member of the Duke faculty. He is board certified in internal medicine and cardiology.

Over his career, Kent has been involved in numerous investigational new drugs and more than 20 successful new drug applications.

Kent increases the size of Intersouth’s investment team to 12.

Other members of the firm’s life-science practice include Dougherty, Bob Bell, Garheng Kong, David Pierson, James Rosen and Phil Tracy.